Drug Type Antibody |
Synonyms |
Target |
Mechanism CXCL13 modulators(CXC13 chemokine ligand modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Preclinical | US | 30 Nov 2022 | |
Solid tumor | Preclinical | US | 30 Nov 2022 |